Pharmacokinetics and tolerability of single‐dose Staccato® alprazolam in adolescents with epilepsy, and population pharmacokinetic analysis to support dose selection in adolescents
Alprazolam was rapidly absorbed in most adolescent patients with epilepsy following administration with the Staccato device. No clinically relevant differences between body weight groups were observed on primary pharmacokinetic or safety outcomes. Staccato alprazolam 2 mg was well tolerated. Overall, the present data support the use of Staccato alprazolam 2 mg in adolescents with epilepsy (12-17 years of age).
Authors
- Aliceson King
- Chiara Rospo
- Pavel Klein (ORCID: https://orcid.org/0000-0001-7244-3722)
- Thomas Wychowski (ORCID: https://orcid.org/0000-0003-1710-4888)
- Robert Roebling (ORCID: https://orcid.org/0009-0003-5402-0808)
- Kore Liow (ORCID: https://orcid.org/0000-0001-6452-9227)
- Jan‐Peer Elshoff (ORCID: https://orcid.org/0000-0001-6366-1525)
- Rik C. Schoemaker (ORCID: https://orcid.org/0000-0002-7538-3005)
- Steven Phillips (ORCID: https://orcid.org/0009-0007-4704-2258)
- Hugues Chanteux (ORCID: https://orcid.org/0000-0002-2222-9813)
- Victor Biton
- Gewalin Aungaroon (ORCID: https://orcid.org/0000-0003-1166-1245)
- Ahmed Sadek (ORCID: https://orcid.org/0000-0003-2436-977X)
Institutions
- Cincinnati Children's Hospital Medical Center (US)
- MultiCare Health System (US)
- Orlando Health (US)
- University of Rochester Medical Center (US)
- Orlando Clinical Research Center (US)
- Arkansas Cardiology (US)
- Hewlett-Packard (Netherlands) (NL)
- Mary Bridge Children's Health Center (US)
- Mid Atlantic Epilepsy and Sleep Center (US)
- UCB Pharma (United States) (US)
- UCB Pharma (Germany) (DE)
- UCB Pharma (Belgium) (BE)
- University of Cincinnati Medical Center (US)
Publication Details
- Journal
- Epilepsia
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1111/epi.18643
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00